BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25163419)

  • 1. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
    Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
    Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
    Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
    J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
    Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
    Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparison of early interim
    Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
    BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma.
    Ma C; Li D; Yin Y; Cao J
    Nucl Med Commun; 2015 Dec; 36(12):1181-6. PubMed ID: 26367213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lee S; Choi Y; Park G; Jo S; Lee SS; Park J; Shim HK
    Technol Cancer Res Treat; 2021; 20():15330338211024655. PubMed ID: 34227434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
    Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
    Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.